Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 304Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

Exercise 2Trastuzumab 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1Lapatinib 1Diet 1Acupuncture Points 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Patient Compliance × Trastuzumab × Clear all
NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡